Drug intelligence / Profile preview

apararenone

Development stage: Phase 2
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral

Overview

Apararenone is a nonsteroidal, highly selective mineralocorticoid receptor antagonist (MRA) developed by Mitsubishi Tanabe Pharma. It acts as an antagonist of the mineralocorticoid (aldosterone) receptor, with high selectivity and potency. Apararenone was primarily investigated for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis (NASH), with previous development also targeting hypertension. The drug is administered orally and has demonstrated a long half-life in clinical studies. Development for all indications appears to have been discontinued after reaching phase I/II trials[1][3][4][7].

Other names: apararenoneN-(4-(4-fluorophenyl)-2,2-dimethyl-3-oxo-1,4-benzoxazin-7-yl)methanesulfonamide

Targets

MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on apararenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on apararenone.

Explore the full profile